argenx SE Stock price

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 11:35:01 2024-02-23 EST After market 14:48:45
377.6 EUR +1.15% Intraday chart for argenx SE 377 -0.17%

Financials

Sales 2023 * 1.11B 1.2B 1.62B Sales 2024 * 1.62B 1.75B 2.37B Capitalization 22.1B 23.91B 32.28B
Net income 2023 * -242M -262M -354M Net income 2024 * -104M -113M -152M EV / Sales 2023 * 17.8 x
Net cash position 2023 * 2.37B 2.56B 3.46B Net cash position 2024 * 2.35B 2.55B 3.44B EV / Sales 2024 * 12.2 x
P/E ratio 2023 *
-89.7 x
P/E ratio 2024 *
-237 x
Employees 843
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.88%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday MT
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo MT
US FDA Accepts for Priority Review Argenx's Biologics License Application for Vyvgart Hytrulo MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy CI
Wolfe Research Starts Argenx With Peer Perform Rating MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Thursday Trading MT
Piper Sandler Adjusts argenx's Price Target to $518 From $515, Keeps Overweight Rating MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients MT
Argenx Says Japan Approved Vyvdura Injection for Generalized Myasthenia Gravis MT
Japanese Health Regulator Approves Argenx's Generalized Myasthenia Gravis Treatment MT
More news
1 day+1.15%
1 week+3.28%
Current month+8.26%
1 month+12.28%
3 months-18.14%
6 months-18.39%
Current year+9.93%
More quotes
1 week
364.00
Extreme 364
379.30
1 month
335.00
Extreme 335
379.30
Current year
328.40
Extreme 328.4
379.30
1 year
271.00
Extreme 271
494.10
3 years
201.40
Extreme 201.4
494.10
5 years
93.05
Extreme 93.05
494.10
10 years
6.23
Extreme 6.23
494.10
More quotes
Managers TitleAgeSince
Founder 52 07-12-31
Director of Finance/CFO 54 21-06-29
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 71 17-04-25
Director/Board Member 73 15-05-12
Director/Board Member 62 16-04-27
More insiders
Date Price Change Volume
24-02-23 377.6 +1.15% 43 520
24-02-22 373.3 +0.92% 64,876
24-02-21 369.9 +0.98% 60,841
24-02-20 366.3 -0.73% 97,262
24-02-19 369 +0.93% 27,743

Real-time Euronext Bruxelles, February 23, 2024 at 11:35 am

More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
373.3 EUR
Average target price
437 EUR
Spread / Average Target
+17.06%
Consensus
1st Jan change Capi.
+9.93% 23 902 M $
+5.76% 110 B $
+10.95% 104 B $
-11.05% 22 243 M $
-26.36% 21 573 M $
-6.59% 18 925 M $
-14.07% 16 036 M $
+1.09% 13 271 M $
+41.50% 12 608 M $
+1.14% 12 102 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock argenx SE - Euronext Bruxelles
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer